Shots:

• The P-II/III COV001 designed to determine the safety- immunogenicity- and efficacy of the AZD1222 (single dose or two doses of AZD1222 at 5x1010 viral particles) vs single dose of meningococcal conjugate vaccine (MenACWY) as control vaccine in up to 1-077 healthy adults aged 18-55yrs. in 5 trial centers in the UK
• The study demonstrated that a single dose of the AZD1222 resulted in 4 times increase in Abs to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. A T-cell response was induced in all the participants- which was maintained two months after vaccination- as per the interim results. The peak response was noted by day 14
• 91% of participants showed neutralizing Abs against SARS-CoV-2 following a single dose of AZD1222 and 100% following a second dose. The levels of neutralizing Abs seen in participants receiving either one/ two doses were in a similar range to those seen in convalescent COVID-19 patients

  Ref: AstraZeneca | Image: AstraZeneca